Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients (PCRTALK)
A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.
Sponsor: British Columbia Cancer Agency
Listed as NCT02010047, this NA trial focuses on Nonsmall Cell Lung Cancer and remains completed. Sponsored by British Columbia Cancer Agency, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Sep 2017 — Jun 2018 [monthly]
Completed NA
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Sep 2017 [monthly]
Unknown Status NA
Status: Enrolling By Invitation → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- British Columbia Cancer Agency
- Insight Genetics
For direct contact, visit the study record on ClinicalTrials.gov .